Search Within

Shanu Modi

Formats
  1. Meeting Abstract (151)
  2. Journal Article (101)
  3. Review (11)
  4. Correspondence (2)
  5. Editorial (2)
  6. Research Letter (1)
Groups
  1. Breast Medicine Service (268)
  2. Department of Medicine (268)
  3. Solid Tumor Oncology Division (268)
  4. Survivorship Research (114)
  5. GSK Faculty (107)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (90)

More Groups

People
  1. Clifford Hudis (79)
  2. Larry Norton (53)
  3. Sarat Chandarlapaty (51)
  4. Sujata Patil (44)
  5. Chau Dang (42)
  6. Komal Jhaveri (35)

More People

Years
  1. 2025 (8)
  2. 2024 (23)
  3. 2023 (15)
  4. 2022 (19)
  5. 2021 (19)
  6. 2020 (21)

More Years

Publications
  1. Journal of Clinical Oncology (66)
  2. Cancer Research (50)
  3. Annals of Oncology (27)
  4. Breast Cancer Research and Treatment (14)
  5. Clinical Cancer Research (10)
  6. Clinical Breast Cancer (8)

More Publications

Publishers
  1. American Society of Clinical Oncology (68)
  2. American Association for Cancer Research (64)
  3. Oxford University Press (33)
  4. Elsevier Inc. (19)
  5. Springer (18)
  6. Nature Publishing Group (13)

More Publishers

Results (268)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Predicting CDK4/6 inhibitors outcomes in pts with HR+/HER2-metastatic breast cancer: A machine learning approach
    Meeting Abstract

    Moiso, E.; Ferraro, E.; Cabel, L.; Safonov, A.; Ahmed, M.; An, J. A. R.; Jhaveri, K. L.; Norton, L.; Robson, M. E.; Modi, S.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Trastuzumab deruxtecan versus treatment of physician’s choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: Subgroup analysis of the DESTINY-Breast04 study
    Journal Article

    Yamashita, T.; Sohn, J. H.; Tokunaga, E.; Niikura, N.; Park, Y. H.; Lee, K. S.; Chae, Y. S.; Xu, B.; Wang, X.; Im, S. A.; more...
    Breast Cancer (2024)

    Fulltext@MSK | Save
  • Analytical and clinical validation of PATHWAY Anti-HER-2/neu (4B5) antibody to assess HER2-low status for trastuzumab deruxtecan treatment in breast cancer
    Journal Article

    Garrido, C.; Manoogian, M.; Ghambire, D.; Lucas, S.; Karnoub, M.; Olson, M. T.; Hicks, D. G.; Tozbikian, G.; Prat, A.; Ueno, N. T.; more...
    Virchows Archiv (2024)

    Fulltext@MSK | Save
  • Trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2–expressing salivary gland carcinoma: A pooled analysis of two phase I studies
    Journal Article

    Takahashi, S.; Bando, H.; Kinoshita, I.; Modi, S.; Tsurutani, J.; Bang, Y. J.; Sato, Y.; Nakatani, S.; Lee, C.; Sugihara, M.; more...
    Japanese Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Open questions, current challenges, and future perspectives in targeting human epidermal growth factor receptor 2-low breast cancer
    Review

    Curigliano, G.; Dent, R.; Earle, H.; Modi, S.; Tarantino, P.; Viale, G.; Tolaney, S. M.
    ESMO Open (2024)

    Fulltext@MSK | Save
  • Management of patients with advanced-stage HER2-positive breast cancer: Current evidence and future perspectives
    Review

    Marra, A.; Chandarlapaty, S.; Modi, S.
    Nature Reviews Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: Updated survival results from a phase II trial (DESTINY-Breast01)
    Journal Article

    Saura, C.; Modi, S.; Krop, I.; Park, Y. H.; Kim, S. B.; Tamura, K.; Iwata, H.; Tsurutani, J.; Sohn, J.; Mathias, E.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • First-in-human evaluation of site-specifically labeled (89)Zr-pertuzumab in patients with HER2-positive breast cancer
    Journal Article

    Yeh, R.; O'Donoghue, J. A.; Jayaprakasam, V. S.; Mauguen, A.; Min, R.; Park, S.; Brockway, J. P.; Bromberg, J. F.; Zhi, W. I.; Robson, M. E.; more...
    Journal of Nuclear Medicine (2024)

    Fulltext@MSK | Save
  • Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): An open-label, randomised, controlled, phase 2 study
    Journal Article

    Tsai, C. J.; Yang, J. T.; Shaverdian, N.; Patel, J.; Shepherd, A. F.; Eng, J.; Guttmann, D.; Yeh, R.; Gelblum, D. Y.; Namakydoust, A.; more...
    Lancet (2024)

    Fulltext@MSK | Save
  • Pruritus related to trastuzumab and pertuzumab in HER2 + breast cancer patients
    Journal Article

    Gu, S.; Dusza, S.; Quigley, E.; Haliasos, H.; Markova, A.; Marchetti, M.; Moy, A. P.; Dang, C.; Modi, S.; Lake, D.; more...
    Breast Cancer Research and Treatment (2024)

    Fulltext@MSK | Save